Sponsored Webinar: Medicare Approach to Sepsis and Quality of Care: What You Need to Know
Presented by Thermo Fisher Scientific
Medicare increasingly views sepsis as one of the most important areas of health care policy, and this is more acute in 2020, since many COVID-19 patients die in septic shock. Medicare uses a complex quality measure, called "SEP-1," which presents challenges for hospitals and has had mixed responses in the peer-reviewed literature. Meanwhile, discussion is turning other measures of care quality and expanded use of biomarkers to guide care in sepsis. This webinar will overview the prevalence of sepsis in the Medicare population, review the SEP-1 measure, and discuss new trends in quality measures in sepsis.
Nurses, physician assistants, physicians, emergency responders, physical therapists, patient care assistants, and other healthcare staff
At the end of the presentation, the learner should be able to:
- Restate the prevalence and features of sepsis in the Medicare population;
- Identify Medicare's current approaches to quality of care in sepsis, and pros and cons of current approaches;
- Discuss new trends in the use of quality measures and biomarkers in sepsis.
Sepsis Alliance gratefully acknowledges the support provided for this sponsor innovation webinar by Thermo Fisher Scientific.
Bruce Quinn, MD, PhD
Principal, Bruce Quinn Associates, LLC
Dr. Bruce Quinn is an expert on health reform, innovation, and Medicare policy. A pathologist by training, he has worked on a wide range of federal health policy issues ranging from biopharma to genomics. He has served as a full-time faculty member at both NYU and Northwestern University schools of medicine. After serving as a physician executive with Medicare, he served as a sciences strategy consultant serving clients of two major law firms, Foley Hoag LLP and Faegre Baker Daniels LLP. Since 2017, Dr. Quinn manages his own medtech and biopharma consulting practice based in Los Angeles and San Francisco. His blog, Discoveries in Health Policy, current logs over 100,000 hits per year. Dr. Quinn has helped leading companies in both medical device and biopharma negotiate with CMS on important policy issues including drug innovation, antibiotics policy, and genomics.
No continuing education credits are offered for this sponsored webinar.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.